DK1375670T3 - Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger - Google Patents

Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger

Info

Publication number
DK1375670T3
DK1375670T3 DK02291550.8T DK02291550T DK1375670T3 DK 1375670 T3 DK1375670 T3 DK 1375670T3 DK 02291550 T DK02291550 T DK 02291550T DK 1375670 T3 DK1375670 T3 DK 1375670T3
Authority
DK
Denmark
Prior art keywords
recombinant
viruses
rna virus
vaccine compositions
virus antigens
Prior art date
Application number
DK02291550.8T
Other languages
English (en)
Inventor
Frederic Tangy
Clarisse Lorin
Lucile Mollet
Frederic Delebecque
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1375670T3 publication Critical patent/DK1375670T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18451—Methods of production or purification of viral material
    • C12N2760/18452—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02291550.8T 2002-06-20 2002-06-20 Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger DK1375670T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291550.8A EP1375670B1 (en) 2002-06-20 2002-06-20 Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions

Publications (1)

Publication Number Publication Date
DK1375670T3 true DK1375670T3 (da) 2013-09-23

Family

ID=29716945

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02291550.8T DK1375670T3 (da) 2002-06-20 2002-06-20 Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
DK10184907.3T DK2290091T3 (da) 2002-06-20 2003-06-20 Rekombinante mæslingevira, som udtrykker epitoper på antigener af RNA-vira samt anvendelse af de rekombinante vira til fremstilling af vacciner
DK03760697.7T DK1516058T3 (da) 2002-06-20 2003-06-20 Rekombinante mæslingevira, som udtrykker epitoper på antigener af RNA-vira, samt anvendelse af de rekombinante vira til fremstilling af vacciner

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10184907.3T DK2290091T3 (da) 2002-06-20 2003-06-20 Rekombinante mæslingevira, som udtrykker epitoper på antigener af RNA-vira samt anvendelse af de rekombinante vira til fremstilling af vacciner
DK03760697.7T DK1516058T3 (da) 2002-06-20 2003-06-20 Rekombinante mæslingevira, som udtrykker epitoper på antigener af RNA-vira, samt anvendelse af de rekombinante vira til fremstilling af vacciner

Country Status (10)

Country Link
US (7) US20060013826A1 (da)
EP (3) EP1375670B1 (da)
KR (1) KR101241423B1 (da)
CN (1) CN1688702B (da)
AU (1) AU2003246373A1 (da)
BR (1) BRPI0312194B8 (da)
CA (2) CA2829581C (da)
DK (3) DK1375670T3 (da)
ES (3) ES2427139T3 (da)
WO (1) WO2004001051A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
ES2330309T3 (es) 2002-06-20 2009-12-09 Institut Pasteur Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas.
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US7427674B2 (en) 2004-04-30 2008-09-23 Baxter International Inc. System and method for detecting West Nile Virus
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
CN106377767A (zh) * 2008-05-26 2017-02-08 卡迪拉保健有限公司 麻疹‑人***瘤组合疫苗
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2012038832A2 (en) * 2010-09-24 2012-03-29 Institut Pasteur Generation of replicating chimeric measles virus - retrovirus particles
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
EP2873728A1 (en) * 2013-11-18 2015-05-20 Institut Pasteur A subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
CN112501138A (zh) * 2014-06-20 2021-03-16 埃克斯-马赛大学 用于快速制备感染性rna病毒的方法
EP2959915A1 (en) 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
EP3103474A1 (en) 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
JP7048482B2 (ja) 2015-08-03 2022-04-05 アメリカ合衆国 Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用
EP3474892A1 (en) 2016-06-24 2019-05-01 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
US11305003B2 (en) 2017-11-09 2022-04-19 Institut Pasteur Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
KR102094096B1 (ko) 2019-02-01 2020-03-26 이준 유희용 수상추진체
WO2022092921A1 (ko) * 2020-10-29 2022-05-05 에스케이바이오사이언스 주식회사 사스-코로나바이러스-2 항원을 포함하는 바이럴 벡터 및 이의 이용
EP4277704A1 (en) * 2021-01-13 2023-11-22 Viroxis Measles-hiv or measles-htlv vaccine
CA3223214A1 (en) * 2021-07-07 2023-01-12 Codagenix Inc. Deoptimized yellow fever virus and methods and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026361A1 (de) * 1980-07-11 1982-02-04 Siemens AG, 1000 Berlin und 8000 München Aus mindestens zwei monolitisch zusammengefassten mis-feldeffekttransistoren bestehender elektrischer widerstand fuer integrierte halbleiterschaltungen
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja) * 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
CA2265519A1 (en) 1996-09-24 1998-04-02 Plant Genetic Systems N.V. Dna-constructs comprising intergenic ribosomal dna and methods to produce proteins using these dna-constructs
JP2000517194A (ja) 1996-09-27 2000-12-26 アメリカン・サイアナミド・カンパニー モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
DE69841690D1 (de) * 1997-02-28 2010-07-08 Acambis Inc Chimäre Impfstoffe gegen Flaviviren
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
JP2003506039A (ja) 1999-08-02 2003-02-18 ワイス ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー
WO2001083794A2 (en) * 2000-04-28 2001-11-08 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious influenza virus
DK1375670T3 (da) * 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
ES2330309T3 (es) 2002-06-20 2009-12-09 Institut Pasteur Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas.
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
CN106377767A (zh) * 2008-05-26 2017-02-08 卡迪拉保健有限公司 麻疹‑人***瘤组合疫苗
MY175250A (en) * 2009-05-05 2020-06-17 Cadila Healthcare Ltd Combined measles-malaria vaccine

Also Published As

Publication number Publication date
US20200095607A1 (en) 2020-03-26
KR20050024359A (ko) 2005-03-10
US20060013826A1 (en) 2006-01-19
US20130052218A1 (en) 2013-02-28
ES2389542T3 (es) 2012-10-29
EP2290091A3 (en) 2011-05-04
US20180195088A1 (en) 2018-07-12
DK2290091T3 (da) 2017-08-28
EP2290091B1 (en) 2017-05-10
EP1516058A2 (en) 2005-03-23
US20210102220A1 (en) 2021-04-08
US20210095315A1 (en) 2021-04-01
BRPI0312194B1 (pt) 2020-12-22
EP2290091A2 (en) 2011-03-02
ES2632723T3 (es) 2017-09-15
CA2829581C (en) 2018-05-01
ES2427139T3 (es) 2013-10-29
EP1375670B1 (en) 2013-06-12
WO2004001051A2 (en) 2003-12-31
US10793877B2 (en) 2020-10-06
CA2829581A1 (en) 2003-12-31
AU2003246373A8 (en) 2004-01-06
KR101241423B1 (ko) 2013-03-12
EP1375670A1 (en) 2004-01-02
CA2493834A1 (en) 2003-12-31
WO2004001051A3 (en) 2004-05-27
AU2003246373A1 (en) 2004-01-06
BR0312194A (pt) 2005-04-26
US20160040187A1 (en) 2016-02-11
EP1516058B1 (en) 2012-06-13
US9914937B2 (en) 2018-03-13
US10519466B2 (en) 2019-12-31
CA2493834C (en) 2013-12-24
BRPI0312194B8 (pt) 2021-05-25
DK1516058T3 (da) 2012-09-17
CN1688702A (zh) 2005-10-26
CN1688702B (zh) 2012-02-22
US9012214B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
DK1375670T3 (da) Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
ECSP045300A (es) Antígenos virales
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
EP1766094A4 (en) INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
DK1781662T3 (da) Inhibitorer af hepatitis C virus RNA-afhængig RNA-polymerase og sammensætninger og behandlinger, der anvender disse
NO20056074L (no) Hoy titer rekombinante influensavira til vaksiner og genterapi
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
NO20082743L (no) Kimaere virus som fremviser ikke-native overflateproteiner samt anvendelse derav
EP1622574A4 (en) EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
EA200700243A1 (ru) Способы лечения гепатита с
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
IL198466A (en) Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines
FR15C0084I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
WO2006131936A3 (en) Hepatitis c virus vaccine
WO2010047830A3 (en) Agents for hcv treatment
MY149395A (en) Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus
DK1694694T3 (da) Replikationskompetent hepatitis C-virus samt anvendelsesfremgangsmåder
NO20040995L (no) Subenhetsvaksine for smittsom bukspyttkjertel-nekrosevirus
CL2004000261A1 (es) Procedimiento para la eliminacion de virus en soluciones de fibrinogeno de aplicacion terapeutica.
WO2006024240A3 (es) Composición vacunal contra el virus de la hepatitis c.
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
TR200201081A3 (tr) Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari